Lijing Li, Global Head of Technical Operations

Lijing Li has over 25 years of academic and industry drug product development experience in areas of AAV gene therapy for rare diseases, stem cell therapy, and Car-T therapy.

Prior to joining Sardocor Corp., she worked at ASC Therapeutics as head of CMC, established CMC platforms, and successfully opened INDs for Hemophilia A gene therapy and allogeneic anti-GVHD cell therapy through process development, GMP manufacturing, and analytical development. Before that, she worked at Cell and Gene therapy companies and City of Hope Beckman Research Institute developing innovative therapeutic products for cancer, rare diseases, and HIV-infected patients. She played key roles in advancing the therapeutics programs.

She was a co-author of multiple peer-reviewed publications. Currently, she is leading CMC and analytical development at Sardocor Corp. to advance gene therapy for the treatment of HFrEF, HFpEF, and DMD/Muscular Dystrophies.